IDH1 and acute myeloid leukemia: Recently, several drugs have been approved by the FDA for AML therapy as follows: a liposomal formulation of daunorubicin and cytarabine (CPX-351); the anti-CD33 antibody drug conjugate gemtuzumab ozogamicin (GO); the IDH1/2 mutant inhibitors ivosidenib and enasidenib; the FLT3 inhibitor midostaurin in combination with chemotherapy and gilteritinib; and the BCL2 inhibitor venetoclax in combination with HMA (116).